FOLR1 and neoplasm: Building on these findings, the single-arm Phase II SORAYA trial focused on a biomarker-enriched population, including only patients with platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers, whose tumors demonstrated ≥75% of tumor cells with moderate to strong FRα membrane staining, as determined by the Ventana FOLR1 assay [16].